Kumar Srinivasan
Director/Board Member at TRANSCENTA HOLDING LIMITED
Net worth: 7 973 $ as of 2024-03-30
Profile
Kumar Srinivasan is currently the President & Chief Executive Officer at Wugen, Inc. He is also a Director at Pulmotect, Inc. and an Independent Non-Executive Director at Transcenta Holding Ltd.
Previously, he worked as the Chief Business Officer & Executive Vice President at Turning Point Therapeutics, Inc. Dr. Srinivasan holds a doctorate degree from Case Western Reserve University, undergraduate and graduate degrees from the University of Madras, and an MBA from The University of Chicago Booth School of Business.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-04-05 | 30,000 ( 0.01% ) | 7 973 $ | 2024-03-30 |
Kumar Srinivasan active positions
| Companies | Position | Start |
|---|---|---|
| TRANSCENTA HOLDING LIMITED | Director/Board Member | 2022-12-18 |
Pulmotect, Inc.
 Pulmotect, Inc. BiotechnologyHealth Technology Pulmotect, Inc. develops clinical stage, novel, pathogen-agnostic, inhaled compound for the prevention and early treatment of acute, severe viral and bacterial respiratory infections. It provides safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague). The company was founded by Brenton Scott and Magnus Hook in 2007 and is headquartered in Houston, TX. | Director/Board Member | - |
Wugen, Inc.
 Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | Chief Executive Officer | 2023-03-12 |
Former positions of Kumar Srinivasan
| Companies | Position | End |
|---|---|---|
| TURG POIN | Corporate Officer/Principal | - |
Training of Kumar Srinivasan
| Case Western Reserve University | Doctorate Degree |
| University of Madras | Graduate Degree |
| The University of Chicago Booth School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| TRANSCENTA HOLDING LIMITED | Health Technology |
| Private companies | 3 |
|---|---|
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Pulmotect, Inc.
Pulmotect, Inc. BiotechnologyHealth Technology Pulmotect, Inc. develops clinical stage, novel, pathogen-agnostic, inhaled compound for the prevention and early treatment of acute, severe viral and bacterial respiratory infections. It provides safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague). The company was founded by Brenton Scott and Magnus Hook in 2007 and is headquartered in Houston, TX. | Health Technology |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | Technology Services |
- Stock Market
- Insiders
- Kumar Srinivasan
